Submitted by art on Tue, 2008-04-08 06:11.
Peptimmune, Inc. a privately held biotechnology company, announced
that it has completed its first clinical trial to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide
copolymer for the treatment of multiple sclerosis and other autoimmune diseases.
PI-2301 is a second generation peptide copolymer from a similar compound class